Category: Bridge Therapeutics

  • Boehringer axes IPF deal with South Korea’s Bridge Therapeutics over toxicity concerns

    Boehringer Ingelheim and South Korea’s Bridge Therapeutics have decided to axe their collaboration over a potential new drug for idiopathic pulmonary fibrosis (IPF), BBT-877. The German pharma had hoped the drug would be a successor to Ofev (nintedanib), which is one of its most important drugs and is approved for the potentially fatal lung-scarring disease. […]